TY - JOUR AU - Molnár, Gergő Attila AU - Vokó, Zoltán AU - Sütő, Gábor AU - Rokszin, György Aurél AU - Nagy, Dávid AU - Surján, György AU - Surján, Orsolya AU - Nagy, Péter AU - Kenessey, István AU - Wéber, András AU - Pálosi, Mihály AU - Müller, Cecília AU - Kásler, Miklós AU - Wittmann, István AU - Kiss, Zoltán TI - Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study) JF - BMJ OPEN DIABETES RESEARCH & CARE J2 - BMJ OPEN DIAB RES CA VL - 12 PY - 2024 IS - 1 PG - 10 SN - 2052-4897 DO - 10.1136/bmjdrc-2023-003777 UR - https://m2.mtmt.hu/api/publication/34538356 ID - 34538356 N1 - * Megosztott szerzőség AB - Introduction Type 2 diabetes mellitus is a risk factor for severe COVID-19 infection and is associated with increased risk of complications. The present study aimed to investigate effectiveness and persistence of different COVID vaccines in persons with or without diabetes during the Delta wave in Hungary.Research design and methods Data sources were the national COVID-19 registry data from the National Public Health Center and the National Health Insurance Fund on the total Hungarian population. The adjusted incidence rate ratios and corresponding 95% CIs were derived from a mixed-effect negative binomial regression model.Results A population of 672 240 cases with type 2 diabetes and a control group of 2 974 102 non-diabetic persons free from chronic diseases participated. Unvaccinated elderly persons with diabetes had 2.68 (95% CI 2.47 to 2.91) times higher COVID-19-related mortality rate as the ‘healthy’ controls. Primary immunization effectively equalized the risk of COVID-19 mortality between the two groups. Vaccine effectiveness declined over time, but the booster restored the effectiveness against mortality to over 90%. The adjusted vaccine effectiveness of the primary Pfizer-BioNTech against infection in the 14–120 days of postvaccination period was 71.6 (95% CI 66.3 to 76.1)% in patients aged 65–100 years with type 2 diabetes and 64.52 (95% CI 59.2 to 69.2)% in the controls. Overall, the effectiveness tended to be higher in individuals with diabetes than in controls. The booster vaccines could restore vaccine effectiveness to over 80% concerning risk of infection (eg, patients with diabetes aged 65–100 years: 89.1 (88.1–89.9)% with Pfizer-on-Pfizer, controls 65–100 years old: 86.9 (85.8–88.0)% with Pfizer-on-Pfizer, or patients with diabetes aged 65–100 years: 88.3 (87.2–89.2)% with Pfizer-on-Sinopharm, controls 65–100 years old: 87.8 (86.8–88.7)% with Pfizer-on-Sinopharm).Conclusions Our data suggest that people with type 2 diabetes may have even higher health gain when getting vaccinated as compared with non-diabetic persons, eliminating the marked, COVID-19-related excess risk of this population. Boosters could restore protection.Data are available upon reasonable request. LA - English DB - MTMT ER - TY - GEN AU - Bánfai, Zsolt AU - Ádám, Valerián AU - Sümegi, Katalin AU - Szabó, András AU - Büki, Gergely AU - Magyari, Lili AU - Hadzsiev, Kinga AU - Kásler, Miklós AU - Melegh, Béla TI - Az erdélyi székelyek alpopuláció-szintű vizsgálata nagy felbontású autoszomális marker adatok alkalmazásával PY - 2023 UR - https://m2.mtmt.hu/api/publication/34655963 ID - 34655963 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Polivka, Lőrinc AU - Vályi-Nagy, István AU - Szekanecz, Zoltán AU - Bogos, Krisztina AU - Vágó, Hajnalka AU - Kamondi, Anita AU - Fekete, Ferenc AU - Szlavik, Janos AU - Surjan, György AU - Surjan, Orsolya AU - Nagy, Péter AU - Schaff, Zsuzsa AU - Kiss, Zoltán AU - Müller, Cecilia AU - Kásler, Miklós AU - Müller, Veronika TI - Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients. Lessons from the Delta Variant TS - Lessons from the Delta Variant JF - VACCINES (BASEL) J2 - VACCINES-BASEL VL - 11 PY - 2023 IS - 12 PG - 12 SN - 2076-393X DO - 10.3390/vaccines11121786 UR - https://m2.mtmt.hu/api/publication/34411671 ID - 34411671 N1 - Funding Agency and Grant Number: Ministry of Human Resources of Hungary Funding text: The Center for Health Technology Assessment of the Semmelweis University participated in the project on a contractual basis with the Ministry of Human Resources of Hungary and received funding. AB - Although the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection against infection and severe disease can still be advantageous, especially for patients with COPD, who are more vulnerable to respiratory infections. The Hungarian COVID-19 registry was retrospectively investigated for risk of infection and hospitalization by time since the last vaccination, and vaccine effectiveness (VE) was calculated in adults with COPD diagnosis and an exact-matched control group during the Delta variant of concern (VOC) wave in Hungary (September–December 2021). For the matching, sex, age, major co-morbidities, vaccination status, and prior infection data were obtained on 23 August 2021. The study population included 373,962 cases divided into COPD patients (age: 66.67 ± 12.66) and a 1:1 matched group (age: 66.73 ± 12.67). In both groups, the female/male ratio was 52.2:47.7, respectively. Among the unvaccinated, there was no difference between groups in risk for infection or hospitalization. Regarding vaccinated cases, in the COPD group, a slightly faster decline in effectiveness was noted for hospitalization prevention, although in both groups, the vaccine lost its significant effect between 215 and 240 days after the last dose of vaccination. Based on a time-stratified multivariate Cox analysis of the vaccinated cases, the hazard was constantly higher in the COPD group, with an HR of 1.09 (95%: 1.05–1.14) for infection and 1.87 (95% CI: 1.59–2.19) for hospitalization. In our study, COPD patients displayed lower vaccine effectiveness against SARS-CoV-2 infection and hospitalization but a similar waning trajectory, as vaccines lost their preventive effect after 215 days. These data emphasize revaccination measures in the COPD patient population. LA - English DB - MTMT ER - TY - JOUR AU - Bánfai, Zsolt AU - Kövesdi, Erzsébet AU - Sümegi, Katalin AU - Büki, Gergely AU - Szabó, András AU - Magyari, Lili AU - Ádám, Valerián AU - Pálos, Ferenc AU - Miseta, Attila János AU - Kásler, Miklós AU - Melegh, Béla TI - Characterization of Danube Swabian population samples on a high-resolution genome-wide basis JF - BMC GENOMICS J2 - BMC GENOMICS VL - 24 PY - 2023 IS - 1 PG - 11 SN - 1471-2164 DO - 10.1186/s12864-022-09092-5 UR - https://m2.mtmt.hu/api/publication/33551270 ID - 33551270 LA - English DB - MTMT ER - TY - BOOK ED - Balogh, Andrea Johanna ED - Gazsó, L. Ferenc ED - Kásler, Miklós / Interviewed person TI - Életközelben: : interjúk a miniszterrel 2020.05.28-2022.03.26 PB - Emberi Erőforrások Minisztériuma CY - Budapest PY - 2022 SP - 187 UR - https://m2.mtmt.hu/api/publication/34757822 ID - 34757822 N1 - A kiadványban szereplő interjúk a QR-kód leolvasásával tekinthetők meg Prof. Dr. Kásler Miklós emberi erőforrások miniszterével készült, nyolcvan videó interjú szerk. kiadása LA - Hungarian DB - MTMT ER - TY - GEN AU - Kásler, Miklós TI - Magyar válaszok a pandémiára PY - 2022 UR - https://m2.mtmt.hu/api/publication/33697346 ID - 33697346 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Neparáczki, Endre AU - Kis, Luca AU - Maróti, Zoltán AU - Kovács, Bence AU - Varga, Gergely István AU - Makoldi, Miklós Zsombor AU - Pamjav, Horolma AU - Teiszler, Éva AU - Tihanyi, Balázs AU - Nagy, Péter L. AU - Maár, Kitti AU - Gyenesei, Attila AU - Schütz, Oszkár AU - Dudás, Eszter AU - Török, Tibor AU - Pascuttini-Juraga, Vesna AU - Peharda, Ivančica AU - Vizi, László Tamás AU - Horváth-Lugossy, Gábor AU - Kásler, Miklós TI - The genetic legacy of the Hunyadi descendants JF - HELIYON J2 - HELIYON VL - 8 PY - 2022 IS - 11 PG - 8 SN - 2405-8440 DO - 10.1016/j.heliyon.2022.e11731 UR - https://m2.mtmt.hu/api/publication/33257861 ID - 33257861 N1 - Cited By :1 Export Date: 19 April 2023 AB - The Hunyadi family is one of the most influential families in the history of Central Europe in the 14th–16th centuries. The family’s prestige was established by Johannes Hunyadi, a Turk-beater who rose to the position of governor of the Kingdom of Hungary. His second son, Matthias Hunyadi, became the elected ruler of the Kingdom of Hungary in 1458. The Hunyadi family had unknown origin. Moreover, Matthias failed to found a dynasty because of lacking a legitimate heir and his illegitimate son Johannes Corvinus was unable to obtain the crown. His grandson, Christophorus Corvinus, died in childhood, thus the direct male line of the family ended. In the framework of on interdisciplinary research, we have determined the whole genome sequences of Johannes Corvinus and Christophorus Corvinus by next-generation sequencing technology. Both of them carried the Y-chromosome haplogroup is E1b1b1a1b1a6a1c ~, which is widespread in Eurasia. The father-son relationship was verified using the classical STR method and whole genome data. Christophorus Corvinus belongs to the rare, sporadically occurring T2c1þ146 mitochondrial haplogroup, most frequent around the Mediterranean, while his father belongs to the T2b mitochondrial haplogroup, widespread in Eurasia, both are consistent with the known origin of the mothers. Archaeogenomic analysis indicated that the Corvinus had an ancient European genome composition. Based on the reported genetic data, it will be possible to identify all the other Hunyadi family member, whose only known grave site is known, but who are resting assorted with several other skeletons. LA - English DB - MTMT ER - TY - GEN AU - Kiss, Zoltán AU - Vokó, Zoltán AU - Sütő, Gábor AU - Molnár, Gergely Attila AU - Nagy, Dávid AU - Surján, György AU - Surján, Orsolya AU - Nagy, Péter AU - Kenessey, István AU - Wéber, András AU - Pálosi, Mihály AU - Müller, Cecília AU - Kásler, Miklós AU - Wittmann, István TI - A Magyarországon alkalmazott koronavírus vakcinák hatékonysága és tartóssága 2-es típusú cukorbetegekben : a Hun-Ve 4 vizsgálat PY - 2022 UR - https://m2.mtmt.hu/api/publication/33241655 ID - 33241655 LA - Hungarian DB - MTMT ER - TY - GEN AU - Sütő, Gábor AU - Vokó, Zoltán AU - Laczy, Boglárka AU - Molnár, Gergő Attila AU - Kiss, Zoltán AU - Nagy, Dávid AU - Surján, György AU - Surján, Orsolya AU - Nagy, Péter AU - Kenessey, István AU - Wéber, András AU - Pálosi, Mihály AU - Müller, Cecília AU - Kásler, Miklós AU - Wittmann, István TI - A koronavírus fertőzés incidenciája, és a fertőzéssel kapcsolatos halálozás 2-es típusú diabeteses betegekben : Hun-Cov-Diab 1 tanulmány PY - 2022 UR - https://m2.mtmt.hu/api/publication/33241545 ID - 33241545 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kenessey, István AU - Szőke, Georgina AU - Dobozi, Mária AU - Szatmári, István AU - Wéber, András AU - Fogarassy, György AU - Nagy, Péter AU - Kásler, Miklós AU - Polgár, Csaba AU - Fogarassyné Vathy, Ágnes TI - Comparison of Cancer Survival Trends in Hungary in the Periods 2001–2005 and 2011–2015 According to a Population-Based Cancer Registry JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 28 PY - 2022 PG - 10 SN - 1219-4956 DO - 10.3389/pore.2022.1610668 UR - https://m2.mtmt.hu/api/publication/33097331 ID - 33097331 N1 - National Institute of Oncology, Budapest, Hungary National Tumor Laboratory Project, Budapest, Hungary Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary Department of Computer Science and Systems Technology, University of Pannonia, Veszprém, Hungary Cancer Surveillance Section, International Agency for Research on Cancer (IARC/WHO), Lyon, France 1st Department of Cardiology, State Hospital for Cardiology, Balatonfüred, Hungary Department of Anatomy and Histology, University of Veterinary Medicine, Budapest, Hungary Institute of Oncochemistry, University of Debrecen, Debrecen, Hungary Department of Oncology, Semmelweis University, Budapest, Hungary Export Date: 20 June 2023 CODEN: POREF Correspondence Address: Kenessey, I.; National Institute of OncologyHungary; email: steveken12@yahoo.com AB - Background: Assessment of population-based cancer survival may provide the most valuable feedback about the effectiveness of oncological surveillance and treatment. LA - English DB - MTMT ER -